Extrawell Pharmaceutical Holdings Full Year 2024 Earnings: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings (HKG:858) Full Year 2024 Results

Key Financial Results

• Net loss: HK$162.9m (down by 226% from HK$129.3m profit in FY 2023).
• HK$0.068 loss per share (down from HK$0.054 profit in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Manufacturing segment contributing a total revenue of HK$59.1m (100% of total revenue). Notably, cost of sales worth HK$30.3m amounted to 51% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling HK$156.4m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how 858's revenue and expenses shape its earnings.

Extrawell Pharmaceutical Holdings shares are down 13% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Extrawell Pharmaceutical Holdings you should be aware of, and 2 of them make us uncomfortable.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com